


Always Better When We're Together: A novel, multi-stakeholder coalition enhances national guidelines for hereditary cancer testing and detection

Emily K. Dalton, Robert Pilarski, Lauren Sferrazza, Jessica Grzybowski, Ann Marie Miller, Shelly Cummings, Kelli Conlan, Kristen Postula, Rebecca Johnson, Lisa Schlager, Robin Dubin, Fred Struve



BACKGROUND

Clinical guidelines must evolve along with ongoing research findings. To assist this, the Inter-Organization Cancer Genetics Clinical Evidence Coalition (INTERACT) was established in 2020 among leading laboratory, industry, and patient groups.



Inter-Organization Cancer Genetics Clinical Coalition

METHODS

- Assess opportunities to expand appropriate testing criteria within guidelines.
- Letters are reviewed and approved by each member organization and submitted through the NCCN submission request process.

CONCLUSIONS

- A diverse group of stakeholders from industry and patient advocacy can successfully work together to increase access to appropriate hereditary cancer testing
- INTERACT has impacted NCCN testing guidelines for hereditary cancer testing through their submission and transparency process
- There is utility and value in coordinated collaboration

Figure 1: Timeline of INTERACT Activities




Figure 2: Highlighted Accepted Requests




Table 1: Detail of NCCN Submission Requests

Submitted	Guideline	Number of Requests	Number approved
11/2020	CRC*	6	1
3/2021	BOP**	8	3
5/2021	Uterine Neoplasms	1	1
8/2021	Gastric Cancer	7	0
11/2021	CRC*	7	1
2/2022	BOP**	7	0
3/2022	Kidney Cancer	3	2
4/2022	Prostate Cancer	3	0
8/2022	Gastric Cancer	3	0
11/2022	CRC*	4	2
3/2023	BOP**	2	1
3/2023	Kidney Cancer	3	2
4/2023	Prostate Cancer	3	Pending
6/2023	Gastric Cancer	4	Pending

* Genetic/Familial High-Risk Assessment: Colorectal

** Genetic/Familial High-Risk Assessment: Breast, Ovarian and Pancreatic

Figure 3: Sample Letter

